



## **STADA UK set for UK Kidney Week Symposium following successful Kinpeygo<sup>®</sup> 4mg<sup>▼</sup> (modified-release hard capsules budesonide) launch and patients starting treatment.**

Prescribing Information can be found [here](#)

- Edinburgh event focused on **‘Advancing the Care of IgAN Patients in the UK’** takes place on 12 June featuring nephrology experts
- April launch of Kinpeygo<sup>®</sup> 4mg<sup>▼</sup> (modified-release budesonide) for treating rare kidney disease, primary immunoglobulin A nephropathy (IgAN), successfully completed – Patients now being treated with the medication across the UK
- New patient and HCP website now live at [Kinpeygo \(kinpeygoatient.co.uk\)](http://kinpeygo.kinpeygoatient.co.uk) featuring treatment guide and other resources.

### **Huddersfield, UK – 05 June 2024 –**

Edinburgh International Conference Centre will see Nephrology experts discuss how best to advance the care of UK IgAN patients on 12 June, with a special event organized by STADA UK as part of UK Kidney Week.

Professor Daniel Gale, St Peter’s Chair of Nephrology, and Chee Kay Cheung, Consultant Nephrologist, will take part in a panel discussion titled **‘Advancing the Care of IgAN Patients in the UK’** sponsored by STADA UK.

The event comes just a few months after the company brought to market Kinpeygo, the country’s first approved treatment for patients with primary IgAN – a progressive, rare kidney disease, which is estimated to affect approximately 14,000 patients in the UK. IgA antibody complexes build up in the kidney, causing inflammation and scarring, which can lead to kidney failure.

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler  
Chairman of the Supervisory Board: Dr. Günter von Au



Upon the National Institute for Health and Care Excellence (NICE) issuing final guidance that recommends targeted-release budesonide as an option for treating primary IgAN, Kinpeygo was described as a ‘game-changer’ for treating patients with IgA nephropathy by Professor Jonathan Barrett, Mayer Professor of Renal Medicine at the University of Leicester.

The treatment is available either through hospital pharmacy or via delivery to the patient’s home, individualising access to treatment to suit both patients and clinicians. With patients identified and prescriptions being written, further support is now being provided online with a patient and HCP website now live at [Kinpeygo \(kinpeygopatient.co.uk\)](https://kinpeygo(kinpeygopatient.co.uk)) featuring a treatment guide and other helpful resources.

“It’s exciting news that Kinpeygo has become the first disease-specific treatment to be approved by NICE for IgA nephropathy, a disease where there has been little to offer to our patients to date,” said Dr Chee Kay Cheung, Consultant Nephrologist and Honorary Associate Professor, University Hospitals of Leicester NHS Trust, and UK Chief Investigator for the Phase 3 NefigArd Trial.

“There is now evidence that treatment with Kinpeygo led to sustained reductions in proteinuria and a clinically significant reduction in loss of kidney function in patients with IgA nephropathy, which may delay or avoid the future need for dialysis or kidney transplantation. Importantly, treatment with Kinpeygo was well-tolerated, providing patients and their clinicians with an effective treatment option in IgAN,” explained Dr Cheung.

Professor Daniel Gale, St Peter’s Chair of Nephrology, is looking forward to taking part in the UK Kidney Week Symposium event, adding: “IgA nephropathy is an important cause of kidney disease worldwide and, because the disease often starts in young people, unfortunately many of those affected have gone on to develop kidney failure.”

“Approval of a first licenced treatment for IgA nephropathy is welcome news and hopefully means that outcomes in this disease will be better in the future than they have been in the past.”

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler  
Chairman of the Supervisory Board: Dr. Günter von Au



STADA UK vice-president Paul Burden described the successful launch and next steps for the treatment roll-out across the UK: “We are delighted that patients are now able to receive Kinpeygo, the UK’s first approved treatment for patients with primary IgAN and STADA UK’s first orphan drug launch. This represents a significant milestone as we add to our growing portfolio of specialty medicines aimed at broadening patient access and adding value to the NHS.”

“Being able to provide treatment for this unmet need within nephrology truly demonstrates the fulfilling of STADA’s purpose of caring for people’s health as a trusted partner.”

#### **EVENT DETAILS:**

**STADA UK presents: Advancing the Care of IgAN Patients in the UK.**

**Venue:** Tinto room at EICC, The Exchange, Edinburgh, Scotland, EH3 8EE

**With:** Professor Daniel Gale, St Peter’s Chair of Nephrology, and Chee Kay Cheung, Consultant Nephrologist.

**When:** Wednesday, 12 June, 8am to 8:45am

**To Register Visit:** [UK Kidney Week \(ukkw.org\)](http://ukkw.org)

**ENDS**

#### **About STADA**

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 115 countries. In financial year 2023, STADA achieved group sales of EUR 3,734.8 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 802.1 million. As of 31 December 2023, STADA employed 11,667 people worldwide.

In the UK we offer a broad portfolio of branded and generic medicines, across a wide range of therapeutic areas, including dermatology, respiratory, oncology, kidney disease, bone health and many more.

STADA UK are committed to providing a reliable supply of cost-effective medicines to all areas of the NHS, and supporting the supply chain to ensure our products are readily accessible to patients.

#### ***Additional information for journalists:***

STADA Arzneimittel AG - Media Relations  
Stadastrasse 2-18  
61118 Bad Vilbel - Germany

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler  
Chairman of the Supervisory Board: Dr. Günter von Au



Phone: +49 (0) 6101 603-165

Fax: +49 (0) 6101 603-215

E-Mail: [press@stada.de](mailto:press@stada.de)

Or visit us on the Internet at [www.stada.com/press](http://www.stada.com/press)

***Additional information for capital market participants:***

STADA Arzneimittel AG - Investor & Creditor Relations

Stadastrasse 2-18

61118 Bad Vilbel – Germany

Phone: +49 (0) 6101 603-4689

Fax: +49 (0) 6101 603-215

E-mail: [ir@stada.de](mailto:ir@stada.de)

Or visit us on the Internet at [www.stada.com/investor-relations](http://www.stada.com/investor-relations)

- [SmPC Information](#)
- [NICE Guidance](#)

<sup>1</sup> NICE Guidance

Adverse events should be reported to Thornton and Ross Limited by emailing [thorntonross@medinformation.co.uk](mailto:thorntonross@medinformation.co.uk) or by calling 01484 848164. Additionally, reporting forms and information can be found at: <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in the Google Play or Apple App Store

Executive Board: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez / Boris Döbler  
Chairman of the Supervisory Board: Dr. Günter von Au